Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 2: response of facets of clinical idiopathic parkinsonism to Helicobacter pylori eradication. A randomized, double-blind, placebo-controlled efficacy study

Links between etiology/pathogenesis of neuropsychiatric disease and infection are increasingly recognized. Proof-of-principle that infection contributes to idiopathic parkinsonism. Randomized, double-blind, placebo-controlled efficacy study of proven Helicobacter pylori eradication on the time cours...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Helicobacter (Cambridge, Mass.) Mass.), 2005-08, Vol.10 (4), p.276-287
Hauptverfasser: Bjarnason, Ingvar T, Bjarnason, Inguar T, Charlett, André, Dobbs, R John, Dobbs, Sylvia M, Ibrahim, Mohammad A A, Kerwin, Robert W, Mahler, Robert F, Oxlade, Norman L, Peterson, Dale W, Plant, J Malcolm, Price, Ashley B, Weller, Clive
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 287
container_issue 4
container_start_page 276
container_title Helicobacter (Cambridge, Mass.)
container_volume 10
creator Bjarnason, Ingvar T
Bjarnason, Inguar T
Charlett, André
Dobbs, R John
Dobbs, Sylvia M
Ibrahim, Mohammad A A
Kerwin, Robert W
Mahler, Robert F
Oxlade, Norman L
Peterson, Dale W
Plant, J Malcolm
Price, Ashley B
Weller, Clive
description Links between etiology/pathogenesis of neuropsychiatric disease and infection are increasingly recognized. Proof-of-principle that infection contributes to idiopathic parkinsonism. Randomized, double-blind, placebo-controlled efficacy study of proven Helicobacter pylori eradication on the time course of facets of parkinsonism. Intervention was 1 week's triple eradication therapy/placebos. Routine deblinding at 1 year (those still infected received open-active), with follow-up to 5 years post-eradication. Primary outcome was mean stride length at free-walking speed, sample size 56 for a difference, active vs. placebo, of 3/4 (between-subject standard deviation). Recruitment of subjects with idiopathic parkinsonism and H. pylori infection was stopped at 31, because of marked deterioration with eradication failure. Interim analysis was made in the 20 who had reached deblinding, seven of whom were receiving antiparkinsonian medication (long-t(1/2), evenly spaced) which remained unchanged. Improvement in stride-length, on active (n = 9) vs. placebo (11), exceeded size of effect on which the sample size was calculated when analyzed on intention-to-treat basis (p = .02), and on protocol analysis of six weekly assessments, including (p = .02) and excluding (p = .05) those on antiparkinsonian medication. Active eradication (blind or open) failed in 4/20, in whom B-lymphocyte count was lower. Their mean time course was: for stride-length, -243 (95% CI -427, -60) vs. 45 (-10, 100) mm/year in the remainder (p = .001); for the ratio, torque to extend to flex relaxed arm, 349 (146, 718) vs. 58 (27, 96)%/ year (p < .001); and for independently rated, visual-analog scale of stance-walk videos (worst-best per individual identical with 0-100 mm), -64 vs. -3 mm from anterior and -50 vs. 11 lateral (p = .004 and .02). Interim analysis points to a direct or surrogate (not necessarily unique) role of a particular infection in the pathogenesis of parkinsonism. With eradication failure, bolus release of antigen from killed bacteria could aggravate an effect of ongoing infection.
doi_str_mv 10.1111/j.1523-5378.2005.00330.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68490711</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17644325</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2293-ae8bfa8479cc51f014158a8c4541c564f1bdfc6cf315d1f940c29457c6fd01a83</originalsourceid><addsrcrecordid>eNqFUk1vFSEUHY3G1upfMKy6ckYYmC93TWNbkyYao2vCwOU9ngyMwEs6_nqZ6VNXRjZwL-fccyCnKBDBFcnr3aEiTU3LhnZ9VWPcVBhTiquHp8X5n4tn-Yx7WjLaD2fFyxgPOCMpG14UZ6QlmA2Mnj-5_OItIK-R3AfvjETGaZDJeIeEU2tlxTSJrWEcSntAOxFT8MYliMk4YVEKQqbft5Ch1u-WjT6LtPc7cBBNXEWMMn7tZZ1ZhO_GxawZpwp9FiGh-j0KEGfv4uZICwlpo0lrsrWs9A8-Sh7dgTXSj9kJBDQv1geDIAiVeav5Cl2hkC35yfwE9RYpfxwtlGOenKvZZq3Rl9K7_DRrQSHQOlPlgmI6quVV8VwLG-H1ab8ovt18-Hp9V95_uv14fXVfyroeaCmgH7XoWTdI2RCNCSNNL3rJGkZk0zJNRqVlKzUljSJ6YFjWA2s62WqFiejpRXH5OHcO_scxfzCfTJRgrXDgj5G3PRtwR8h_gaRrGaN1k4H9I1AGH2MAzedgJhEWTjBfw8QPfM0MXzPD1zDxLUz8IVPfnDSO4wTqL_GUHvoLVorOUQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17644325</pqid></control><display><type>article</type><title>Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 2: response of facets of clinical idiopathic parkinsonism to Helicobacter pylori eradication. A randomized, double-blind, placebo-controlled efficacy study</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Bjarnason, Ingvar T ; Bjarnason, Inguar T ; Charlett, André ; Dobbs, R John ; Dobbs, Sylvia M ; Ibrahim, Mohammad A A ; Kerwin, Robert W ; Mahler, Robert F ; Oxlade, Norman L ; Peterson, Dale W ; Plant, J Malcolm ; Price, Ashley B ; Weller, Clive</creator><creatorcontrib>Bjarnason, Ingvar T ; Bjarnason, Inguar T ; Charlett, André ; Dobbs, R John ; Dobbs, Sylvia M ; Ibrahim, Mohammad A A ; Kerwin, Robert W ; Mahler, Robert F ; Oxlade, Norman L ; Peterson, Dale W ; Plant, J Malcolm ; Price, Ashley B ; Weller, Clive</creatorcontrib><description>Links between etiology/pathogenesis of neuropsychiatric disease and infection are increasingly recognized. Proof-of-principle that infection contributes to idiopathic parkinsonism. Randomized, double-blind, placebo-controlled efficacy study of proven Helicobacter pylori eradication on the time course of facets of parkinsonism. Intervention was 1 week's triple eradication therapy/placebos. Routine deblinding at 1 year (those still infected received open-active), with follow-up to 5 years post-eradication. Primary outcome was mean stride length at free-walking speed, sample size 56 for a difference, active vs. placebo, of 3/4 (between-subject standard deviation). Recruitment of subjects with idiopathic parkinsonism and H. pylori infection was stopped at 31, because of marked deterioration with eradication failure. Interim analysis was made in the 20 who had reached deblinding, seven of whom were receiving antiparkinsonian medication (long-t(1/2), evenly spaced) which remained unchanged. Improvement in stride-length, on active (n = 9) vs. placebo (11), exceeded size of effect on which the sample size was calculated when analyzed on intention-to-treat basis (p = .02), and on protocol analysis of six weekly assessments, including (p = .02) and excluding (p = .05) those on antiparkinsonian medication. Active eradication (blind or open) failed in 4/20, in whom B-lymphocyte count was lower. Their mean time course was: for stride-length, -243 (95% CI -427, -60) vs. 45 (-10, 100) mm/year in the remainder (p = .001); for the ratio, torque to extend to flex relaxed arm, 349 (146, 718) vs. 58 (27, 96)%/ year (p &lt; .001); and for independently rated, visual-analog scale of stance-walk videos (worst-best per individual identical with 0-100 mm), -64 vs. -3 mm from anterior and -50 vs. 11 lateral (p = .004 and .02). Interim analysis points to a direct or surrogate (not necessarily unique) role of a particular infection in the pathogenesis of parkinsonism. With eradication failure, bolus release of antigen from killed bacteria could aggravate an effect of ongoing infection.</description><identifier>ISSN: 1083-4389</identifier><identifier>EISSN: 1523-5378</identifier><identifier>DOI: 10.1111/j.1523-5378.2005.00330.x</identifier><identifier>PMID: 16104943</identifier><language>eng</language><publisher>England</publisher><subject>Amoxicillin - therapeutic use ; Anti-Bacterial Agents - therapeutic use ; Anti-Ulcer Agents - therapeutic use ; Chronic Disease ; Clarithromycin - therapeutic use ; Double-Blind Method ; Drug Therapy, Combination ; Helicobacter Infections - complications ; Helicobacter Infections - drug therapy ; Helicobacter Infections - microbiology ; Helicobacter pylori - drug effects ; Humans ; Inflammation ; Omeprazole - therapeutic use ; Parkinson Disease - drug therapy ; Parkinson Disease - etiology ; Parkinson Disease - microbiology ; Parkinson Disease - physiopathology ; Treatment Outcome</subject><ispartof>Helicobacter (Cambridge, Mass.), 2005-08, Vol.10 (4), p.276-287</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2293-ae8bfa8479cc51f014158a8c4541c564f1bdfc6cf315d1f940c29457c6fd01a83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16104943$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bjarnason, Ingvar T</creatorcontrib><creatorcontrib>Bjarnason, Inguar T</creatorcontrib><creatorcontrib>Charlett, André</creatorcontrib><creatorcontrib>Dobbs, R John</creatorcontrib><creatorcontrib>Dobbs, Sylvia M</creatorcontrib><creatorcontrib>Ibrahim, Mohammad A A</creatorcontrib><creatorcontrib>Kerwin, Robert W</creatorcontrib><creatorcontrib>Mahler, Robert F</creatorcontrib><creatorcontrib>Oxlade, Norman L</creatorcontrib><creatorcontrib>Peterson, Dale W</creatorcontrib><creatorcontrib>Plant, J Malcolm</creatorcontrib><creatorcontrib>Price, Ashley B</creatorcontrib><creatorcontrib>Weller, Clive</creatorcontrib><title>Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 2: response of facets of clinical idiopathic parkinsonism to Helicobacter pylori eradication. A randomized, double-blind, placebo-controlled efficacy study</title><title>Helicobacter (Cambridge, Mass.)</title><addtitle>Helicobacter</addtitle><description>Links between etiology/pathogenesis of neuropsychiatric disease and infection are increasingly recognized. Proof-of-principle that infection contributes to idiopathic parkinsonism. Randomized, double-blind, placebo-controlled efficacy study of proven Helicobacter pylori eradication on the time course of facets of parkinsonism. Intervention was 1 week's triple eradication therapy/placebos. Routine deblinding at 1 year (those still infected received open-active), with follow-up to 5 years post-eradication. Primary outcome was mean stride length at free-walking speed, sample size 56 for a difference, active vs. placebo, of 3/4 (between-subject standard deviation). Recruitment of subjects with idiopathic parkinsonism and H. pylori infection was stopped at 31, because of marked deterioration with eradication failure. Interim analysis was made in the 20 who had reached deblinding, seven of whom were receiving antiparkinsonian medication (long-t(1/2), evenly spaced) which remained unchanged. Improvement in stride-length, on active (n = 9) vs. placebo (11), exceeded size of effect on which the sample size was calculated when analyzed on intention-to-treat basis (p = .02), and on protocol analysis of six weekly assessments, including (p = .02) and excluding (p = .05) those on antiparkinsonian medication. Active eradication (blind or open) failed in 4/20, in whom B-lymphocyte count was lower. Their mean time course was: for stride-length, -243 (95% CI -427, -60) vs. 45 (-10, 100) mm/year in the remainder (p = .001); for the ratio, torque to extend to flex relaxed arm, 349 (146, 718) vs. 58 (27, 96)%/ year (p &lt; .001); and for independently rated, visual-analog scale of stance-walk videos (worst-best per individual identical with 0-100 mm), -64 vs. -3 mm from anterior and -50 vs. 11 lateral (p = .004 and .02). Interim analysis points to a direct or surrogate (not necessarily unique) role of a particular infection in the pathogenesis of parkinsonism. With eradication failure, bolus release of antigen from killed bacteria could aggravate an effect of ongoing infection.</description><subject>Amoxicillin - therapeutic use</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Anti-Ulcer Agents - therapeutic use</subject><subject>Chronic Disease</subject><subject>Clarithromycin - therapeutic use</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination</subject><subject>Helicobacter Infections - complications</subject><subject>Helicobacter Infections - drug therapy</subject><subject>Helicobacter Infections - microbiology</subject><subject>Helicobacter pylori - drug effects</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Omeprazole - therapeutic use</subject><subject>Parkinson Disease - drug therapy</subject><subject>Parkinson Disease - etiology</subject><subject>Parkinson Disease - microbiology</subject><subject>Parkinson Disease - physiopathology</subject><subject>Treatment Outcome</subject><issn>1083-4389</issn><issn>1523-5378</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUk1vFSEUHY3G1upfMKy6ckYYmC93TWNbkyYao2vCwOU9ngyMwEs6_nqZ6VNXRjZwL-fccyCnKBDBFcnr3aEiTU3LhnZ9VWPcVBhTiquHp8X5n4tn-Yx7WjLaD2fFyxgPOCMpG14UZ6QlmA2Mnj-5_OItIK-R3AfvjETGaZDJeIeEU2tlxTSJrWEcSntAOxFT8MYliMk4YVEKQqbft5Ch1u-WjT6LtPc7cBBNXEWMMn7tZZ1ZhO_GxawZpwp9FiGh-j0KEGfv4uZICwlpo0lrsrWs9A8-Sh7dgTXSj9kJBDQv1geDIAiVeav5Cl2hkC35yfwE9RYpfxwtlGOenKvZZq3Rl9K7_DRrQSHQOlPlgmI6quVV8VwLG-H1ab8ovt18-Hp9V95_uv14fXVfyroeaCmgH7XoWTdI2RCNCSNNL3rJGkZk0zJNRqVlKzUljSJ6YFjWA2s62WqFiejpRXH5OHcO_scxfzCfTJRgrXDgj5G3PRtwR8h_gaRrGaN1k4H9I1AGH2MAzedgJhEWTjBfw8QPfM0MXzPD1zDxLUz8IVPfnDSO4wTqL_GUHvoLVorOUQ</recordid><startdate>200508</startdate><enddate>200508</enddate><creator>Bjarnason, Ingvar T</creator><creator>Bjarnason, Inguar T</creator><creator>Charlett, André</creator><creator>Dobbs, R John</creator><creator>Dobbs, Sylvia M</creator><creator>Ibrahim, Mohammad A A</creator><creator>Kerwin, Robert W</creator><creator>Mahler, Robert F</creator><creator>Oxlade, Norman L</creator><creator>Peterson, Dale W</creator><creator>Plant, J Malcolm</creator><creator>Price, Ashley B</creator><creator>Weller, Clive</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>200508</creationdate><title>Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 2: response of facets of clinical idiopathic parkinsonism to Helicobacter pylori eradication. A randomized, double-blind, placebo-controlled efficacy study</title><author>Bjarnason, Ingvar T ; Bjarnason, Inguar T ; Charlett, André ; Dobbs, R John ; Dobbs, Sylvia M ; Ibrahim, Mohammad A A ; Kerwin, Robert W ; Mahler, Robert F ; Oxlade, Norman L ; Peterson, Dale W ; Plant, J Malcolm ; Price, Ashley B ; Weller, Clive</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2293-ae8bfa8479cc51f014158a8c4541c564f1bdfc6cf315d1f940c29457c6fd01a83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Amoxicillin - therapeutic use</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Anti-Ulcer Agents - therapeutic use</topic><topic>Chronic Disease</topic><topic>Clarithromycin - therapeutic use</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination</topic><topic>Helicobacter Infections - complications</topic><topic>Helicobacter Infections - drug therapy</topic><topic>Helicobacter Infections - microbiology</topic><topic>Helicobacter pylori - drug effects</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Omeprazole - therapeutic use</topic><topic>Parkinson Disease - drug therapy</topic><topic>Parkinson Disease - etiology</topic><topic>Parkinson Disease - microbiology</topic><topic>Parkinson Disease - physiopathology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bjarnason, Ingvar T</creatorcontrib><creatorcontrib>Bjarnason, Inguar T</creatorcontrib><creatorcontrib>Charlett, André</creatorcontrib><creatorcontrib>Dobbs, R John</creatorcontrib><creatorcontrib>Dobbs, Sylvia M</creatorcontrib><creatorcontrib>Ibrahim, Mohammad A A</creatorcontrib><creatorcontrib>Kerwin, Robert W</creatorcontrib><creatorcontrib>Mahler, Robert F</creatorcontrib><creatorcontrib>Oxlade, Norman L</creatorcontrib><creatorcontrib>Peterson, Dale W</creatorcontrib><creatorcontrib>Plant, J Malcolm</creatorcontrib><creatorcontrib>Price, Ashley B</creatorcontrib><creatorcontrib>Weller, Clive</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Helicobacter (Cambridge, Mass.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bjarnason, Ingvar T</au><au>Bjarnason, Inguar T</au><au>Charlett, André</au><au>Dobbs, R John</au><au>Dobbs, Sylvia M</au><au>Ibrahim, Mohammad A A</au><au>Kerwin, Robert W</au><au>Mahler, Robert F</au><au>Oxlade, Norman L</au><au>Peterson, Dale W</au><au>Plant, J Malcolm</au><au>Price, Ashley B</au><au>Weller, Clive</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 2: response of facets of clinical idiopathic parkinsonism to Helicobacter pylori eradication. A randomized, double-blind, placebo-controlled efficacy study</atitle><jtitle>Helicobacter (Cambridge, Mass.)</jtitle><addtitle>Helicobacter</addtitle><date>2005-08</date><risdate>2005</risdate><volume>10</volume><issue>4</issue><spage>276</spage><epage>287</epage><pages>276-287</pages><issn>1083-4389</issn><eissn>1523-5378</eissn><abstract>Links between etiology/pathogenesis of neuropsychiatric disease and infection are increasingly recognized. Proof-of-principle that infection contributes to idiopathic parkinsonism. Randomized, double-blind, placebo-controlled efficacy study of proven Helicobacter pylori eradication on the time course of facets of parkinsonism. Intervention was 1 week's triple eradication therapy/placebos. Routine deblinding at 1 year (those still infected received open-active), with follow-up to 5 years post-eradication. Primary outcome was mean stride length at free-walking speed, sample size 56 for a difference, active vs. placebo, of 3/4 (between-subject standard deviation). Recruitment of subjects with idiopathic parkinsonism and H. pylori infection was stopped at 31, because of marked deterioration with eradication failure. Interim analysis was made in the 20 who had reached deblinding, seven of whom were receiving antiparkinsonian medication (long-t(1/2), evenly spaced) which remained unchanged. Improvement in stride-length, on active (n = 9) vs. placebo (11), exceeded size of effect on which the sample size was calculated when analyzed on intention-to-treat basis (p = .02), and on protocol analysis of six weekly assessments, including (p = .02) and excluding (p = .05) those on antiparkinsonian medication. Active eradication (blind or open) failed in 4/20, in whom B-lymphocyte count was lower. Their mean time course was: for stride-length, -243 (95% CI -427, -60) vs. 45 (-10, 100) mm/year in the remainder (p = .001); for the ratio, torque to extend to flex relaxed arm, 349 (146, 718) vs. 58 (27, 96)%/ year (p &lt; .001); and for independently rated, visual-analog scale of stance-walk videos (worst-best per individual identical with 0-100 mm), -64 vs. -3 mm from anterior and -50 vs. 11 lateral (p = .004 and .02). Interim analysis points to a direct or surrogate (not necessarily unique) role of a particular infection in the pathogenesis of parkinsonism. With eradication failure, bolus release of antigen from killed bacteria could aggravate an effect of ongoing infection.</abstract><cop>England</cop><pmid>16104943</pmid><doi>10.1111/j.1523-5378.2005.00330.x</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1083-4389
ispartof Helicobacter (Cambridge, Mass.), 2005-08, Vol.10 (4), p.276-287
issn 1083-4389
1523-5378
language eng
recordid cdi_proquest_miscellaneous_68490711
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Amoxicillin - therapeutic use
Anti-Bacterial Agents - therapeutic use
Anti-Ulcer Agents - therapeutic use
Chronic Disease
Clarithromycin - therapeutic use
Double-Blind Method
Drug Therapy, Combination
Helicobacter Infections - complications
Helicobacter Infections - drug therapy
Helicobacter Infections - microbiology
Helicobacter pylori - drug effects
Humans
Inflammation
Omeprazole - therapeutic use
Parkinson Disease - drug therapy
Parkinson Disease - etiology
Parkinson Disease - microbiology
Parkinson Disease - physiopathology
Treatment Outcome
title Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 2: response of facets of clinical idiopathic parkinsonism to Helicobacter pylori eradication. A randomized, double-blind, placebo-controlled efficacy study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T09%3A37%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20chronic%20infection%20and%20inflammation%20in%20the%20gastrointestinal%20tract%20in%20the%20etiology%20and%20pathogenesis%20of%20idiopathic%20parkinsonism.%20Part%202:%20response%20of%20facets%20of%20clinical%20idiopathic%20parkinsonism%20to%20Helicobacter%20pylori%20eradication.%20A%20randomized,%20double-blind,%20placebo-controlled%20efficacy%20study&rft.jtitle=Helicobacter%20(Cambridge,%20Mass.)&rft.au=Bjarnason,%20Ingvar%20T&rft.date=2005-08&rft.volume=10&rft.issue=4&rft.spage=276&rft.epage=287&rft.pages=276-287&rft.issn=1083-4389&rft.eissn=1523-5378&rft_id=info:doi/10.1111/j.1523-5378.2005.00330.x&rft_dat=%3Cproquest_cross%3E17644325%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17644325&rft_id=info:pmid/16104943&rfr_iscdi=true